FRANKLIN, Mass., May 5 /PRNewswire-FirstCall/ -- PLC Systems Inc. (Amex: PLC) announced today that it expects to release to the news wire its financial results for the first quarter ended March 31, 2008 before the market opens on Thursday, May 15, 2008. The company plans to host a conference call to discuss those results at 11:00 a.m. ET on that same day.
The call may be joined via telephone by dialing (800) 638-4930 or (617) 614-3944 (for international participants) at least five minutes prior to the start of the call. The conference ID code is: 63587177. A live webcast of the conference call will be available by visiting the PLC Systems website, www.plcmed.com five minutes before the call begins. The webcast will be archived on this site starting one hour after the call is completed. In addition, a telephonic replay of the call will be available beginning at 1:00 p.m. ET on May 15, 2008, through midnight on May 22, 2008, and can be accessed by dialing (888) 286-8010 or (617) 801-6888 (for international participants), using conference ID code 30142513.
About PLC Systems Inc.
PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world's first TMR angina relief device cleared for commercial distribution by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare, and to obtain a CE Mark for European distribution.
The company completed a pilot clinical safety study of its RenalGuard Therapy(TM) and RenalGuard System(TM) and has received its CE Mark Certificate for RenalGuard System. PLC recently received FDA conditional approval to commence a U.S. pivotal trial to study the effectiveness of its RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy (CIN). RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys. This therapy is based on the theory that creating and maintaining a high urine output is beneficial to patients undergoing imaging procedures where contrast agents are used. The real-time measurement and matched fluid replacement design of the RenalGuard System is intended to ensure that a high urine flow is maintained before, during and after these procedures. This should allow the body to rapidly eliminate contrast, reducing its toxic effects. The RenalGuard System, with its matched fluid replacement capability, is intended to minimize the risk of over- or under-hydration.
Additional company information can be found at www.plcmed.com.
PLC Systems, PLC Medical Systems, PLC, CO2 Heart Laser, RenalGuard, RenalGuard System and RenalGuard Therapy are trademarks of PLC Systems Inc.
SOURCE PLC Systems Inc.